Nanograb

Executive Summary

Nanograb is a UK-based biotechnology company leveraging an AI-powered platform to solve critical challenges in gene therapy: non-specific delivery and low efficiency. Founded in 2018 and headquartered in London, the company aims to precisely deliver genetic material to target cells, potentially revolutionizing treatments for genetic disorders, cancers, and other diseases. The platform combines nanotechnology with machine learning to design and optimize delivery vectors, addressing a key bottleneck in the gene therapy field. While still in early stages with no disclosed funding rounds or pipelines, Nanograb's approach could position it as a leader in next-generation gene delivery if it achieves proof-of-concept in preclinical studies. The company operates in a competitive landscape but its AI-first strategy differentiates it from traditional viral and non-viral delivery methods. Near-term success depends on advancing its platform through in vitro and in vivo validation, securing strategic partnerships, and attracting investment to fuel research. As gene therapies continue to gain regulatory approvals and market traction, Nanograb's technology could become a critical enabler for the industry, offering safer and more effective delivery solutions.

Upcoming Catalysts (preview)

• Q4 2025Preclinical Proof-of-Concept Data Release50% success
• H1 2026Series A Funding Announcement60% success
• H2 2026Strategic Partnership with Gene Therapy Developer40% success